Polysomnography (PSG) is the gold-standard diagnostic tool for evaluating sleep disorders in patients with neurodegenerative diseases. For individuals with atypical Parkinsonian syndromes such as Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP), PSG serves multiple critical functions: diagnosing REM Sleep Behavior Disorder (RBD), evaluating sleep architecture, detecting sleep-disordered breathing, and providing essential diagnostic information that helps differentiate between synucleinopathies and tauopathies[@schenck2024].
The importance of PSG in this patient population cannot be overstated. Sleep abnormalities are among the earliest and most predictive biomarkers of specific neurodegenerative pathologies. While REM Sleep Behavior Disorder strongly suggests an underlying synucleinopathy (Parkinson's Disease, Multiple System Atrophy, Dementia with Lewy Bodies), its absence in a patient with parkinsonian features increases the probability of a tauopathy such as CBD or PSP[@koga2024].
The recommended PSG montage for neurodegenerative disease evaluation includes:
| Channel Type | Electrodes/Montage | Purpose |
|---|---|---|
| EEG | C3/A2, C4/A1, O1/A2, O2/A1, F3/A2, F4/A1 | Sleep staging, detection of seizures, periodic limb movements |
| EOG | Left outer canthus (LOC), Right outer canthus (ROC) | Eye movement detection for REM sleep identification |
| EMG - Chin | Submental EMG (2 channels) | Muscle tone assessment for REM atonia |
| EMG - Limb | Bilateral anterior tibialis, bilateral flexor digitorum superficialis | Periodic limb movement detection |
| Respiratory | Nasal pressure cannula, oral thermistor, chest and abdominal effort belts | Apnea/hypopnea detection |
| Cardiac | Single-channel ECG (modified lead II) | Arrhythmia detection, HRV analysis |
| Pulse Oximetry | Continuous SpO2 monitoring | Oxygen desaturation events |
| Position | Position sensor | Supine vs. lateral sleep analysis |
The diagnostic polysomnography study typically includes[@american2024]:
If sleep-disordered breathing is detected, a second night for CPAP/BiPAP titration may be required.
RBD is diagnosed based on the International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria, which require polysomnographic demonstration of REM sleep without atonia (RSWA)[@sixeldring2024].
Tonic EMG Activity:
Phasic EMG Activity:
Combined Criteria:
Patients with neurodegenerative diseases demonstrate characteristic sleep architecture changes:
| Parameter | Typical Finding in Neurodegeneration |
|---|---|
| Total Sleep Time | Reduced (fragmented sleep) |
| Sleep Efficiency | Reduced (<80%) |
| REM Sleep Percentage | May be increased in early PD, decreased in advanced disease |
| REM Latency | Variable; reduced in PD with RBD |
| N1 Sleep | Increased (light sleep fragmentation) |
| N2 Sleep | Variable |
| N3 Sleep | Decreased (reduced slow-wave sleep) |
| Wake After Sleep Onset (WASO) | Increased |
| Periodic Limb Movements in Sleep (PLMS) | Present in >80% of RBD cases |
Sleep apnea is common in neurodegenerative disease patients and may[@iranzo2023]:
Central apnea patterns may be particularly relevant in Multiple System Atrophy due to autonomic dysfunction.
The presence or absence of RBD provides critical information for distinguishing between neurodegenerative disease subtypes:
| Disease | RBD Prevalence | Diagnostic Implication |
|---|---|---|
| Multiple System Atrophy (MSA) | 69-90% | Strongly suggests synucleinopathy |
| Dementia with Lewy Bodies (DLB) | 50-80% | Core diagnostic feature |
| Parkinson's Disease (PD) | 30-50% | Suggests more diffuse disease |
| Progressive Supranuclear Palsy (PSP) | 0-13% | Absence supports tauopathy |
| Corticobasal Degeneration (CBD) | 0-8% | Absence supports tauopathy |
| Alzheimer's Disease (AD) | <5% | Rare, suggests mixed pathology |
For patients with Corticobasal Syndrome (CBS) or PSP[@ferman2024]:
In the absence of RBD, the following PSG findings may support tauopathy diagnosis:
The MSLT is a daytime nap study performed the day following PSG to assess excessive daytime sleepiness (EDS) and sleep onset REM periods (SOREMPs)[@littner2024].
| MSL Result | SOREMPs | Clinical Interpretation |
|---|---|---|
| >10 minutes | 0-1 | Normal |
| 8-10 minutes | 2 | Mild EDS |
| 5-8 minutes | 2 | Moderate EDS |
| <5 minutes | ≥2 | Severe EDS; consider narcolepsy |
In neurodegenerative disease[@arnulf2024]:
For CBD and PSP patients, MSLT findings may include:
PSG should be considered in the following scenarios for patients with atypical parkinsonism[@st2024]:
Patient with Atypical Parkinsonism (CBS/PSP)
│
▼
Clinical Sleep Assessment
(Sleep history, bedtime partner interview)
│
▼
RBD Screening Questionnaire (RBDQ)
│
▼
Score > 5 ──────> Polysomnography (PSG)
│
▼
Diagnosis:
- RBD present → Synucleinopathy workup
- RBD absent → Confirm tauopathy
- Sleep apnea → CPAP titration
| Service | Typical Cost (USD) | Insurance Coverage |
|---|---|---|
| Diagnostic PSG | $1,500-3,000 | Typically covered with sleep disorder symptoms |
| CPAP Titration | $1,000-2,000 | Covered if AHI > 15 |
| MSLT | $800-1,500 | May require prior authorization |
| Home Sleep Test | $300-500 | Limited to uncomplicated sleep apnea |
The PSG findings directly inform the Personalized Treatment Plan for Atypical Parkinsonism: